BHC Bausch Health Companies Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 885590 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY10.8%
TTM net income YoY-332.3%
TTM EPS YoY-332.0%
Revenue 3-yr CAGR9.2%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin11.2%
Net margin-7.6%
FCF margin16.8%
EBITDA margin21.6%
Returns
ROE—
ROA-3.2%
ROIC (approx.)5.5%
Asset turnover0.42x
Leverage & solvency
Liabilities / assets101.3%
Debt / equity—
Current ratio1.56x
Interest coverage0.78x
Cash quality & payout
Operating cash flow / net income-2.63x
Accruals ratio-11.7%
Payout ratio—
Capex / revenue3.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.94B | $2.85B | $2.52B | $2.80B | $2.68B | $2.53B | $2.26B | $2.56B |
| R&D expense | $141.00M | $173.00M | $163.00M | $161.00M | $166.00M | $159.00M | $143.00M | $163.00M |
| SG&A expense | $834.00M | $907.00M | $861.00M | $882.00M | $795.00M | $894.00M | $867.00M | $820.00M |
| Operating income | $983.00M | $740.00M | -$950.00M | $474.00M | $619.00M | $444.00M | $276.00M | $558.00M |
| Interest expense | $398.00M | $396.00M | $402.00M | $397.00M | $412.00M | $465.00M | $330.00M | $337.00M |
| Pretax income | $597.00M | $348.00M | -$1.35B | $56.00M | $218.00M | $140.00M | -$47.00M | $209.00M |
| Income tax | $151.00M | $88.00M | $77.00M | $159.00M | $37.00M | $12.00M | $39.00M | $111.00M |
| Net income | $436.00M | $258.00M | -$1.42B | -$112.00M | $179.00M | $148.00M | -$58.00M | $93.00M |
| EBITDA | $1.27B | $1.02B | -$655.00M | $764.00M | $925.00M | $751.00M | $581.00M | $865.00M |
| EPS (basic) | 1.16 | 0.69 | -3.82 | — | 0.48 | 0.40 | -0.16 | — |
| EPS (diluted) | 1.15 | 0.68 | -3.82 | — | 0.48 | 0.40 | -0.16 | — |
| Weighted avg. shares (diluted) | 380.70M | 378.10M | 372.80M | — | 375.50M | 373.10M | 369.60M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $2.48B | $1.82B | $1.30B | $1.31B | $1.31B | $1.73B | $1.13B | $1.20B |
| Receivables | $2.53B | $2.26B | $2.19B | $2.35B | $2.42B | $2.21B | $2.07B | $2.14B |
| Inventory | $1.59B | $1.60B | $1.60B | $1.63B | $1.60B | $1.66B | $1.61B | $1.59B |
| Current assets | $7.41B | $6.52B | $5.98B | $6.16B | $6.25B | $6.51B | $5.73B | $5.77B |
| PP&E, net | $2.11B | $2.10B | $2.10B | $2.07B | $2.03B | $1.99B | $1.88B | $1.78B |
| Goodwill | $9.77B | $9.79B | $9.81B | $11.27B | $11.29B | $11.30B | $11.15B | $11.09B |
| Intangibles | $3.97B | $4.18B | $4.40B | $4.64B | $4.83B | $5.05B | $5.30B | $5.55B |
| Total assets | $25.48B | $24.79B | $24.50B | $26.37B | $26.82B | $27.27B | $26.42B | $26.52B |
| Current liabilities | $4.75B | $4.54B | $4.53B | $4.18B | $4.79B | $4.97B | $4.26B | $6.75B |
| Short-term debt | $866.00M | $866.00M | $889.00M | $225.00M | $579.00M | $879.00M | $282.00M | $2.67B |
| Long-term debt | $19.77B | $19.88B | $19.88B | $20.59B | $20.46B | $20.86B | $21.23B | $18.94B |
| Total debt | $20.64B | $20.74B | $20.76B | $20.82B | $21.04B | $21.74B | $21.51B | $21.62B |
| Total liabilities | $25.82B | $25.60B | $25.58B | $25.99B | $26.47B | $27.12B | $26.66B | $26.84B |
| Shareholders' equity | -$1.33B | -$1.77B | -$2.06B | -$554.00M | -$565.00M | -$764.00M | -$1.18B | -$1.28B |
| Net debt | $18.15B | $18.92B | $19.46B | $19.51B | $19.73B | $20.01B | $20.38B | $20.41B |
| Shares outstanding | 374.25M | 373.90M | 373.46M | 370.53M | 370.47M | 369.75M | 369.54M | 367.84M |
| Cash flow statement | ||||||||
| Operating cash flow | $814.00M | $670.00M | $230.00M | $495.00M | $405.00M | $289.00M | $211.00M | $601.00M |
| Capital expenditure | $66.00M | $77.00M | $109.00M | $92.00M | $91.00M | $99.00M | $115.00M | $106.00M |
| Free cash flow | $748.00M | $593.00M | $121.00M | $403.00M | $314.00M | $190.00M | $96.00M | $495.00M |
| Investing cash flow | -$83.00M | -$93.00M | -$139.00M | -$282.00M | -$83.00M | -$100.00M | -$130.00M | -$200.00M |
| Financing cash flow | -$80.00M | -$49.00M | -$100.00M | -$235.00M | -$719.00M | $358.00M | -$146.00M | $85.00M |
| Depreciation & amortization | $284.00M | $281.00M | $295.00M | $290.00M | $306.00M | $307.00M | $305.00M | $307.00M |
| Stock-based compensation | $52.00M | $54.00M | $52.00M | $84.00M | $43.00M | $46.00M | $43.00M | $43.00M |
Free plan shows the latest 8 periods; Pro shows all 70 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.